1198-46-5

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-6-methoxy-9H-purine is used as a potential antiviral agent due to its pharmacological properties, which are currently under investigation. It may offer therapeutic benefits in treating viral infections by interfering with viral replication or other mechanisms.
Used in Organic Synthesis:
2-chloro-6-methoxy-9H-purine serves as a building block in the synthesis of other bioactive compounds. Its unique structure allows it to be a valuable component in creating new molecules with potential applications in medicine and other fields.
Used in Synthetic Organic Chemistry:
2-chloro-6-methoxy-9H-purine is utilized in the development of synthetic organic chemistry methods, contributing to the advancement of chemical synthesis techniques and the creation of novel chemical entities with diverse applications.

Upstream product

• 20535-83-5 O<6>-methylguanine 
• 5451-40-1 2,6 dichloropurine 
• 67-56-1 methanol 
• 124-41-4 sodium methylate 
• 146196-07-8 2-chloro-9-(2'deoxy-β-D-erythro-pentofuranosyl)-6-methoxy-9H-purine 

Downstream Products

• 1275582-97-2 N²-(3,4-dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine 
• 1338696-08-4 9-benzyl-2-chloro-6-methoxypurine 
• 1370371-06-4 7-benzyl-2-chloro-6-methoxy-7H-purine 
• 1389318-46-0 tert-butyl (2-chloro-6-methoxy-9H-purin-9-yl)(cyclohexyl)methylcarbamate 
• 1318254-92-0 2-chloro-6-methoxy-9-phenyl-9H-purine 

Relevant academic research and scientific papers

Determination of 2-chloro-2'-deoxyadenosine (antileukemic agent) and related compounds by electrochemical method

Electrochemical method for determination of 2-chloro-2'-deoxyadenosine and related compounds modified in exocyclic 6-NH2 group is described. Electrochemical detection of investigated compounds, based on the electrooxidation process of the adenine moiety, has been performed in aqueous solutions, in the pH range 2-9, on a glassy carbon electrode.

Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof

The invention relates to compounds of formula (I): The compounds are useful as antibacterial agents, especially again Clostridium difficile-associated diseases.

LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME

Compounds having the formula (I), (II), (III) are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.

Discovery of a pyrrolopyrimidine (JH-II-127), a highly potent, selective, and brain penetrant LRRK2 inhibitor

Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target. Here we report a 2-anilino-4-methylamino-5-chloropyrrolopyrimidine, JH-II-127 (18

Stereocontrolled approach for the syntheses of 3-isopurine nucleosides: 3-(2-deoxy-β-d-ribofuranosyl)xanthine and isoguanine by intramolecular glycosylation

3-Isopurine nucleosides, namely 3-(ribofuranosyl)purine nucleosides, are interesting owing to their potential biological activity and as components of modified oligonucleotides. A regio- and stereocontrolled method was developed for the synthesis of β-2′-

6-Oxo and 6-thio purine analogs as antimycobacterial agents

6-Oxo and 6-thio analogs of purine were prepared based on the initial activity screening of a small, diverse purine library against Mycobacterium tuberculosis (Mtb). Certain 6-oxo and 6-thio-substituted purine analogs described herein showed moderate to good inhibitory activity. N 9-substitution apparently enhances the anti-mycobacterial activity in the purine series described herein. Several 2-amino and 2-chloro purine analogs were also synthesized that showed moderate inhibitory activity against Mtb.

Synthesis and cytotoxic activity of some new 2,6-substituted purines

A seriesof twenty four acyclic unsaturated 2,6-substututed purines 5a-20b were synthesized. These compounds were evaluated for cytotoxic activity against NCI-60 DTP human tumor cell line screen at 10?Mconcentration. N 9-[(Z)-4′-chloro-2′-butenyl-1′-yl]-2, 6-dichloropurine(5a), N9-[4′-chloro-2′-butynyl-1′- yl]-2,6-dichloropurine(10a), N9-[(E)-2′,3′-dibromo- 4′-chloro-2′-butenyl-1′-yl]-6-methoxypurine(14)and N 9-[4′-chloro-2′-butynyl-1′-yl]-6-(4-methoxyphenyl) -purine(19)exhibited highly potent cytotoxic activity with GI50 values in the 1-5 μM range for most human tumor cell lines. Other compounds exhibited moderate activity.

Synthesis of some biologically active halogenopurines

A series of some biologically active halogenopurines were synthesized from commercially available guanine (1). The reaction of guanine with acetic anhydride yielded 2,9-diacetylguanine (2-1) by acetylation reaction. Further treatment of 2-1 with POCl3 by PEG-2000 phase transfer catalysis furnished the important compound 3a, then 2-amino-6-halogenopurines (3b-d) were obtained through chlorine-exchange halogenations between KX and 3a by TPPB phase transfer catalyst. Further, 2-halogenopurines (2-2a-d, 4-2a-d, 5a-d) were efficiently prepared from 2-amino-6-substituted purines (1, 3a, 4-1) via a diazotization catalyzed by their corresponding CuX, and some new compounds 2-2a, 2-2c, 2-2d, 4-2c, 4-2d, 5b, 5c and 5d have been discovered. The structures of synthesized compounds were mainly established on the basis of their elemental analysis, 1H NMR, as well as their mass spectral data. All the title compounds were screened for their antifungal activities, and some of the compounds showed promising activity.